DexCom Stock: 3 Growth Factors Driving Investor Interest
DexCom is attracting considerable investor attention as a promising growth stock, driven by the company’s potential for exceptional returns. However, identifying truly exceptional growth stocks isn’t straightforward; many carry elevated risk and volatility, and investments based on overhyped growth stories frequently lead to substantial losses. Recognizing high-potential growth stocks is now facilitated by the Zacks Growth Style Score, a component of the broader Zacks Style Scores system, which goes beyond conventional growth metrics to rigorously analyze a company’s genuine growth prospects. This score has identified DexCom (DXCM) as a particularly compelling investment option at this time, offering a favorable Growth Score alongside a leading Zacks Rank.
Historically, research has demonstrated that stocks exhibiting the strongest growth characteristics consistently outperform the broader market. When combined with a Growth Score of ‘A’ or ‘B’ and a Zacks Rank of #1 (Strong Buy) or #2 (Buy), the returns generated by these stocks are notably enhanced. Investors are increasingly focused on fundamental elements when evaluating a stock’s potential, and several key factors contribute to DexCom’s strong position. These factors highlight the company’s considerable growth potential and warrant careful consideration.
One of the most critical aspects for growth investors is earnings growth. The ability of a company to consistently increase its profit levels is a primary driver of stock value. DexCom’s historical earnings per share (EPS) growth rate stands at 25%, a figure that significantly surpasses the industry average, which is currently pegged at 14%. This projected growth of 23.8% for the current year indicates a substantial upward trajectory, demonstrating the company’s strong competitive positioning and ability to capitalize on market opportunities. This robust EPS growth reflects confidence in the company’s ability to generate future profitability, driving shareholder value.
Beyond earnings, cash flow growth is another vital indicator of a company’s financial health and growth potential. For growth-oriented businesses, a high accumulation of cash allows for strategic investment in new projects and initiatives without reliance on costly external financing. DexCom’s current year-over-year cash flow growth rate is 9.8%, substantially exceeding the industry average of -0.7%. This positive cash flow accumulation underscores the company’s efficient operations and its capacity to fund future expansion. Furthermore, analyzing the historical cash flow growth rate – which has averaged 32% over the past three to five years, compared to the industry average of 6.5% – provides valuable context, showcasing the company’s consistent performance and its capacity to generate sustainable cash flows.
The reliability of a stock’s growth prospects can also be assessed by examining the trend in earnings estimate revisions. A positive trend in revisions suggests growing confidence among analysts, which often translates to increased investor interest and potential stock price appreciation. There has been a notable increase in the Zacks Consensus Estimate for DexCom’s current year earnings, rising by 0.1% over the past month. This upward trend in estimates reflects a growing recognition of the company’s strong fundamentals and positive outlook. Combining a ‘B’ Growth Score, driven by the previously highlighted factors, with DexCom’s Zacks Rank #2, further solidifies the company’s attractiveness to growth-focused investors.
The convergence of these positive indicators – the Growth Score, the Zacks Rank, and the upward trend in earnings estimate revisions – positions DexCom as a well-supported investment. With a strategic blend of robust growth prospects, a leading market ranking, and a favorable earnings outlook, growth investors are encouraged to closely monitor DexCom’s performance. To receive more recommendations, investors can download the "7 Best Stocks for the Next 30 Days" report, available now from Zacks Investment Research.
